Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Jia Shen Tablets in Chronic Heart Failure
NCT06348498Phase 1Recruiting
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Jiashen Tablets in chronic heart failure (CHF), sponsored by Tasly Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum observed plasma concentration at Day 84, Time to reach peak or maximum observed concentration at Day 84 and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
Jiashen Tablets
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT06348498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06348498.